AntibioTx Invited to Present at Berlin Antimicrobial Conference
COPENHAGEN, NOVEMBER 14, 2016 – Worldwide we a see a need for action against AMR and AntibioTx is highly aware of something has to be done. The 10th Berlin Conference on Life Sciences […]
AntibioTx Concludes 28-day Repeat Dosing in Göttingen Minipigs with Positive Results
COPENHAGEN, SEPTEMBER 19, 2016 – A 28-day repeat dosing study in Göttingen minipigs concluded that proprietary formulations of ATx201 are well tolerated and leads to very low systemic exposure. BioAdvice, a […]
AntibioTx Invited to Publish ATx201 Results at the ‘2nd Inflammatory Skin Disease Summit’ (New York)
COPENHAGEN, SEPTEMBER 06, 2016 – AntibioTx has been invited to present recent positive results with ATx201 at the ‘2nd Inflammatory Skin Disease Summit’ symposium in New York the 16-20th November 2016. The ‘2nd […]
AntibioTx Enters Collaboration with Dr. Keith Bostian to Establish Medicinal Chemistry Program
COPENHAGEN, AUGUST 19, 2016 – Dr. Keith Bostian is a well-renowned figure within science of medicine and has extensive experience with biotechnology industry entrepreneurship and has had executive operating roles in […]
In vivo Efficacy Studies of ATx201 Compares Favorably with Marketed Products
COPENHAGEN, AUGUST 07, 2016 – Recent in vivo studies in mice documents the antibacterial properties of ATx201 and that they compare favorably to marketed products. The CSO of AntibioTx, Dr. Morten […]
Horizon2020 Grant Awarded to Consortium (Train2Target) Comprising AntibioTx
COPENHAGEN, MAY 16, 2016 – AntibioTx and the Train2Target consortium, comprising leading academic groups and SME’s in the antimicrobial space, has been awarded a Horizon2020 grant to fund research and development. […]
Collaboration Initiated with Prof. Mylonakis (Brown University) to Further Elucidate MoA and New Indication Opportunities
COPENHAGEN, APRIL 07, 2016 – AntibioTx welcomes the collaboration with Professor Mylonakis and foresees it as a very important step towards extracting the compound class potentials. Professor Mylonakis is an expert […]
In vivo Study in Minipigs Confirmed Systemic Safety and No Genotoxicity of ATx201
COPENHAGEN, MARCH 22, 2016 – AntibioTx detected no systemic availability of ATx201 after the application in Hanford minipigs. The study protocol consisted of applying ATx201 twice a day for 28-days, followed […]
AntibioTx Rewarded Grant Funding to Conduct Phase 1 and Phase 2 Studies in Atopic Dermatitis Patients
COPENHAGEN, OCTOBER 26, 2015 – AntibioTx has been rewarded grant funding from The Innovation Fund Denmark to further develop a candidate developed on the basis of extensive compound screening models. […]
